Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $12.11 Analyst target: $12.50 Upside: 3.22%
Amarin Corporation plc, a pharmaceutical company, is engaged in the development and commercialization of therapies for the treatment of cardiovascular disease in the United States. The company is headquartered in Dublin, Ireland.
See the full interactive analysis & chart →Informational only — not investment advice.